{
  "id": 10456548,
  "title": "Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study",
  "url": "https://urgent.news/2026/09/28/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T13:34:49.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo-033-ras-mutant-mss-colorectal-cancer-study"
  },
  "original_language": "en",
  "account": null,
  "summary": "Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026 FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival SAN DIEGO, […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}